CanSino Biologics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.11-01

CanSino Biologics (HKG:6185) Third Quarter 2024 ResultsKey Financial Results Revenue: CN¥263.6m (up 76% from 3Q 2023). Net income: CN¥2.96m (up from CN¥143.6m loss in 3Q 2023). Profit margin: 1.1% (up...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480070706?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2024-11-01 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480070706","market":"sg","top_or_hot":-1,"title":"CanSino Biologics Third Quarter 2024 Earnings: Beats Expectations","media":"Simply Wall St.","content":"<div>\n<p>CanSino Biologics (HKG:6185) Third Quarter 2024 ResultsKey Financial Results Revenue: CN¥263.6m (up 76% from 3Q 2023). Net income: CN¥2.96m (up from CN¥143.6m loss in 3Q 2023). Profit margin: 1.1% (up...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-third-quarter-2024-earnings-beats-expectat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics Third Quarter 2024 Earnings: Beats Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics Third Quarter 2024 Earnings: Beats Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-third-quarter-2024-earnings-beats-expectat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CanSino Biologics (HKG:6185) Third Quarter 2024 ResultsKey Financial Results Revenue: CN¥263.6m (up 76% from 3Q 2023). Net income: CN¥2.96m (up from CN¥143.6m loss in 3Q 2023). Profit margin: 1.1% (up...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-third-quarter-2024-earnings-beats-expectat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-third-quarter-2024-earnings-beats-expectat","article_id":"2480070706","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480070706","pubTimestamp":1730424734,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CanSino Biologics ( HKG:6185 ) Third Quarter 2024 Results Key Financial Results Revenue: CN¥263.6m (up 76% from 3Q...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","TTM":"塔塔汽车","BK1161":"生物科技","BK4523":"印度概念","BK7104":"黄金","BK1574":"生物医药B类股","TTM.AU":"TITAN MINERALS LTD","06185":"康希诺生物","BK1191":"制药","BK4099":"汽车制造商"},"translate_title":"康希诺生物2024年第三季度盈利：超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1,"TTM":1,"TTM.AU":1},"content_text":"CanSino Biologics (HKG:6185) Third Quarter 2024 ResultsKey Financial Results Revenue: CN¥263.6m (up 76% from 3Q 2023). Net income: CN¥2.96m (up from CN¥143.6m loss in 3Q 2023). Profit margin: 1.1% (up from net loss in 3Q 2023). EPS: CN¥0.012 (up from CN¥0.58 loss in 3Q 2023).  SEHK:6185 Earnings and Revenue Growth November 1st 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period CanSino Biologics Revenues and Earnings Beat Expectations  Revenue exceeded analyst estimates by 22%.  Earnings per share (EPS) also surpassed analyst estimates.      Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Hong Kong.    Performance of the Hong Kong Biotechs industry.  The company's shares are up 14% from a week ago.   Risk Analysis You should always think about risks. Case in point, we've spotted   1 warning sign for CanSino Biologics  you should be aware of.  New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480070706"}